一项2026年印度研究发现,SGLT2和DPP-4抑制剂改善了二型糖尿病患者的血糖控制. A 2026 Indian study found SGLT2 and DPP-4 inhibitors improved blood sugar control in type 2 diabetes patients on metformin.

根据对90名接受甲胺治疗的患者进行的一项试验结果,在印度于2026年3月18日完成的AMPLIFY-TIR研究发现,结合SGLT2和DPP-4抑制剂显著改善了患有2型糖尿病的印度成人的血糖控制和稳定性. The AMPLIFY-TIR Study, completed in India on March 18, 2026, found that combining SGLT2 and DPP-4 inhibitors significantly improved blood sugar control and stability in Indian adults with type 2 diabetes, according to results from a trial involving 90 patients on metformin. 这项在6个地点进行的研究由CliniExperts作为首席监管人员负责,该研究使用了持续血糖监测并报告了一个有利的安全性概况,没有新的问题. Conducted across six sites and led by CliniExperts as the CRO, the study used continuous glucose monitoring and reported a favorable safety profile with no new concerns. 这些发现支持这种联合治疗作为印度人口有效的治疗策略. The findings support this combination therapy as an effective treatment strategy for the Indian population.